Sign in

BICX on OTC

BioCorRx Inc.

BioCorRx Inc. is a specialty outpatient facilities services company, listed on OTC (BICX).1 It is headquartered in Anaheim, California.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Elite Health Systems Inc., Concentra Group Holdings Parent, Inc. or Acadia Healthcare, or pick any stock.

  • TickerBICX on OTC1
  • IndustryServices-Specialty Outpatient Facilities, NEC1
  • HeadquartersAnaheim, California1
  • Business address2390 East Orangewood Avenue, Suite 570, Anaheim, Ca 928062
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We were incorporated as Cetrone Energy Company on January 28, 2008 in the State of Nevada. From inception until we completed our reverse acquisition of Fresh Start Private, Inc. (“FSP”), the principal business of the Company originally was to develop “green” renewable fuel sources for agricultural operations, specifically biodiesel. On July 26, 2010, we filed an amendment to our articles of incorporation changing our name to Fresh Start Private Management, Inc. During that time, we had no revenue and our operations were limited to capital formation, organization, and development of our business plan and target customer market. As a result of the reverse acquisition of FSP, on October 31, 2011, we ceased our prior operations and we are now a holding company and our wholly owned subsidiary engages in alcoholism and opioid addiction treatment through our BioCorRx® Recovery Program and relat…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-606.0%Operating margin4
-431.5%Net margin4
10301.1%Revenue growth, 20254

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development31¢$1.8M
  • Selling, general and admin66¢$3.8M
  • Interest4¢$223.8K

Out of $797.2K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$797.2K in 2025+232% since 2019
0$200.0K$400.0K$600.0K$800.0K2019: $240.3K$240.3K20192020: $122.6K$122.6K2020−49%2021: $48.3K$48.3K2021−61%2022: $213.8K$213.8K2022+343%2023: $89.2K$89.2K2023−58%2024: $7.7K$7.7K2024−91%2025: $797.2K$797.2K2025+10301%
Operating income567894-$4.8M in 2025−13% since 2019
-$8.0M-$6.0M-$4.0M-$2.0M02019: -$5.6M-$5.6M20192020: -$7.5M-$7.5M2020+35%2021: -$5.5M-$5.5M2021−26%2022: -$4.7M-$4.7M2022−15%2023: -$3.8M-$3.8M2023−19%2024: -$5.1M-$5.1M2024+35%2025: -$4.8M-$4.8M2025−6%
Net income567894-$3.4M in 2025−43% since 2019
-$8.0M-$6.0M-$4.0M-$2.0M02019: -$6.0M-$6.0M20192020: -$3.5M-$3.5M2020−42%2021: -$5.2M-$5.2M2021+49%2022: -$4.4M-$4.4M2022−16%2023: -$3.8M-$3.8M2023−14%2024: -$5.1M-$5.1M2024+35%2025: -$3.4M-$3.4M2025−33%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenues, net$797.2K$7.7K
Cost of implants and other costs$21.8K$1.7K
Research and development$1.8M$1.5M
Selling, general and administrative$3.8M$3.6M
Depreciation and amortization$44.0K$33.1K
Total operating expenses$5.6M$5.1M
Loss from operations-$4.8M-$5.1M
Interest expense - related parties-$637.7K-$750.8K
Interest expense, net-$223.8K-$776.8K
Loss on settlement of debt-$187.5K-$164.6K
Grant income$2.4M$1.5M
Change in fair value of upfront purchase price liability-$7.4K$0
Change in fair value of royalty liability-$279.5K$0
Other miscellaneous income$223.0K$129.3K
Total other (expenses) income, net$1.3M-$89.6K
Loss before provision for income taxes-$3.5M-$5.2M
Income taxes$0$0
Net loss-$3.5M-$5.2M
Non-controlling interest$68.6K$106.0K
Net loss attributable to BioCorRx Inc.-$3.4M-$5.1M
Net loss per common share, basic and diluted-$0.19-$0.49
Weighted average number of common shares outstanding, basic and diluted18.5M shares10.5M shares

Compare BioCorRx Inc. with another company

What it owns

What BioCorRx Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$194.6K4 Dec 31, 2025$194.6K4 Dec 31, 20240%
Accumulated depreciation$190.5K4 Dec 31, 2025$175.6K4 Dec 31, 2024+8.5%
Property and equipment, net$4.1K4 Dec 31, 2025$19.0K4 Dec 31, 2024−78.6%
Operating-lease assets (leased space)$159.1K4 Dec 31, 2025$199.2K4 Dec 31, 2024−20.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$563.2K4 Dec 31, 2025$04 Dec 31, 2024
Finite-lived intangibles, gross$600.9K4 Dec 31, 2025$15.2K4 Dec 31, 2024+3853.3%
Accumulated amortization-$36.4K4 Dec 31, 2025-$7.4K4 Dec 31, 2024−395.6%
Finite-lived intangibles, net$564.5K4 Dec 31, 2025$7.8K4 Dec 31, 2024+7092.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$143.4K4 Dec 31, 2025$04 Dec 31, 2024
Raw materials$116.1K4 Dec 31, 2025$04 Dec 31, 2024
Work in process$04 Dec 31, 2025$04 Dec 31, 2024
Finished goods$27.3K4 Dec 31, 2025$04 Dec 31, 2024

Properties, in its own words

We do not own any real estate or other physical properties material to our operations. Our executive offices are located at 2390 East Orangewood Avenue, Suite 570, Anaheim, California 92806, and our telephone number is (714) 462-4880. We lease this property. On April 9, 2024, we and our landlord agreed that we would move to a larger space within the building that currently houses its principal executive offices. We extended the term of our lease for an additional 60 months beginning approximately May 1, 2024 (upon the landlord’s completion of the work on the new space). The extended term expires on April 30, 2029. The extended lease has payments of $4,545 per month.

Item 2 of the 10-K filed Mar 31, 2026.3

Leadership

Who has led BioCorRx Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jorge Andrade Jr.2013
  2. Kent Emry2013–2014
  3. Brady James Granier2016–2020
  4. Lourdes Felix2021–2025

President

  1. Neil Terrence Muller Mr.2013–2014
  2. Brady James Granier2016–2024
  3. Lourdes Felix2020
  4. Louis C. Lucido2024–2025

Chief financial officer

  1. Lourdes Felix2013–2025

Chief operating officer

  1. Brady James Granier2013–2014
  2. Lourdes Felix2016–2020
201520202025
Board members and other officers (10)

Former names

  • FRESH START PRIVATE MANAGEMENT, INC.Nov 18, 2010 to Feb 4, 20142
  • Cetrone Energy COSep 9, 2008 to Nov 15, 20102

Timeline

  1. Sep 4, 20268-K Executive or director change29
  2. Apr 2, 20268-K Entered a material agreement; Unregistered sale of shares30
  3. Aug 1, 20258-K Entered a material agreement; Unregistered sale of shares31
  4. Mar 11, 20258-K Entered a material agreement; Unregistered sale of shares; Other events32
  5. Jul 10, 20248-K Change of auditor33
  6. Apr 3, 20248-K Executive or director change34
  7. Jan 5, 20248-K Executive or director change35
  8. Dec 15, 20238-K Entered a material agreement; Unregistered sale of shares36
  9. Nov 16, 20238-K Entered a material agreement; Unregistered sale of shares37
  10. Nov 2, 20238-K Executive or director change38
  11. Apr 11, 20238-K Entered a material agreement39
  12. Apr 5, 20238-K Entered a material agreement; Unregistered sale of shares40
  13. Jan 5, 2021New chief executive Lourdes Felix becomes CEO13
  14. Jun 21, 2016New chief executive Brady James Granier becomes CEO14
  15. Oct 24, 2013New chief executive Kent Emry becomes CEO16
  16. Mar 1, 2013New chief executive Jorge Andrade Jr. becomes CEO15

Filings

113 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 18 major events, 75 insider forms. The latest 20:

  1. Sep 4, 20268-K EDGAR
  2. Aug 14, 202610-Q EDGAR
  3. May 15, 202610-Q EDGAR
  4. Apr 2, 20268-K EDGAR
  5. Mar 31, 202610-K EDGAR
  6. Nov 14, 202510-Q EDGAR
  7. Aug 14, 202510-Q EDGAR
  8. Aug 1, 20258-K EDGAR
  9. May 15, 202510-Q EDGAR
  10. Mar 31, 202510-K EDGAR
  11. Mar 11, 20258-K EDGAR
  12. Jan 31, 20254 EDGAR
  13. Jan 31, 20254 EDGAR
  14. Nov 14, 202410-Q EDGAR
  15. Aug 13, 202410-Q EDGAR
  16. Jul 10, 20244 EDGAR
  17. Jul 10, 20248-K EDGAR
  18. Jul 8, 20244 EDGAR
  19. Jul 8, 20244 EDGAR
  20. Jun 3, 20244 EDGAR

The 113 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

19 open-market trades by officers, directors and large owners since October 2021: 19 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 16, 2024Lucido Louis C.PresidentBuy126$0.70$88Form 4
Jan 12, 2024Lucido Louis C.PresidentBuy3,000$0.70$2.1KForm 4
Apr 3, 2023Lucido Louis C.PresidentBuy171,296$1.75$299.8KForm 4
Mar 29, 2023GALLIGAN JOSEPH JDirectorBuy171,296$1.75$299.8KForm 4
Jan 30, 2023Lucido Louis C.PresidentBuy400$1.39$554Form 4
Jan 26, 2023Lucido Louis C.PresidentBuy500$1.29$645Form 4
Jan 24, 2023Lucido Louis C.PresidentBuy200$1.20$240Form 4
Jan 13, 2023Lucido Louis C.PresidentBuy4,000$1.12$4.5KForm 4
Jan 3, 2023Lucido Louis C.PresidentBuy2,000$1.10$2.2KForm 4
Dec 30, 2022Lucido Louis C.PresidentBuy315$1.00$314Form 4
Dec 12, 2022Lucido Louis C.PresidentBuy5,000$0.83$4.2KForm 4
Oct 6, 2022Lucido Louis C.PresidentBuy580$1.87$1.1KForm 4
Oct 5, 2022Lucido Louis C.PresidentBuy1,000$2.02$2.0KForm 4
Sep 6, 2022Lucido Louis C.PresidentBuy10$2.10$21Form 4
Aug 31, 2022Lucido Louis C.PresidentBuy610$2.12$1.3KForm 4
Aug 29, 2022Lucido Louis C.PresidentBuy3,268$2.11$6.9KForm 4
Aug 26, 2022Lucido Louis C.PresidentBuy560$2.12$1.2KForm 4
Aug 25, 2022Lucido Louis C.PresidentBuy500$2.18$1.1KForm 4
Oct 19, 2021Lucido Louis C.PresidentBuy1,550$3.20$5.0KForm 4

From Forms 4 filed with the SEC.

SEC filer profile

How BioCorRx Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBioCorRx Inc.1
  • CIK0001443863
  • Employer ID (EIN)90-09674473
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)8093 Services-Specialty Outpatient Facilities, NEC1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address2390 East Orangewood Avenue, Suite 570, Anaheim, CA 928061
  • Phone(714) 462-48801
  • Shares outstanding29,758,177 as of Aug 14, 202612
  • Public float$2.9M as of Jun 30, 20253
  • AuditorM&K CPAS, PLLC, Woodlands, TX PCAOB ID 2738; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceSep 9, 20081
  • Filings499 in all: 4 (175), 8-K (131), 10-Q (54), 10-K (18), UPLOAD (17), NT 10-Q (11), 3 (10), 8-K/A (10)1
    All 30 form types

    NT 10-K (9), CORRESP (8), 10-Q/A (6), CT ORDER (5), DEF 14C (5), PRE 14C (5), 4/A (4), PRER14C (4), 10-K/A (3), EFFECT (3), S-1 (3), S-8 (3), 144 (2), POS AM (2), S-8 POS (2), SC 13D (2), SC 13G (2), 424A (1), 8-A12G (1), D (1), RW (1), S-1/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Latest 8-K (8-K) Sep 4, 2026

Risk factors and legal proceedings

The risks BioCorRx Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 28 risks under these headings, as written.3

  • RISKS RELATED TO OUR COMPANY
  • We have received an opinion from our independent registered public accounting firm expressing substantial doubt regarding our ability to continue as a going concern.
  • We have a history of operating losses, anticipate future losses and may never be profitable.
  • If we are unable to obtain additional financing, business operations will be harmed and if we do obtain additional financing then existing shareholders may suffer substantial dilution.
  • If more licensed providers do not agree to offer our programs to their patients, our program may not achieve market acceptance and we may not become profitable.
  • The use of our programs could result in product liability or similar claims that could be expensive, damage our reputation and harm our business.
  • Our success is substantially dependent on the continued service of our senior management.
  • We may not be able to hire or retain other key personnel required for our business, which could disrupt the development and sales of our products and limit our ability to grow.
  • Our officers and directors have significant control over shareholder matters and the minority shareholders will have little or no control over our affairs.
  • The Unavailability, Reduction or Elimination of Government Incentives Could Have a Material Adverse Effect on Our Business, Financial Condition, Operating Results and Prospects.
  • We are subject to regulations of various local and federal government agencies and if we are unable to comply with such regulations it would materially affect our business.
  • The commercial success of our programs and products will depend upon the degree of market acceptance by physicians, hospitals, third-party payors, and others in the medical community.
The other 17 risks
  • We may not have sufficient resources to effectively introduce and market our services and products, which could materially harm our operating results.
  • Health care legislation, including the Patient Protection and Affordable Care Act and the Health Insurance Portability and Accountability Act of 1996, may have a material adverse effect on us.
  • We may not be able to protect or enforce our intellectual property rights, which could impair our competitive position.
  • Expenses incurred with respect to monitoring, protecting, and defending our intellectual property rights could adversely affect our business.
  • Our failure to secure trademark registrations could adversely affect our ability to market our product candidates and our business.
  • We may not be able to adequately protect our intellectual property outside of the United States.
  • We operate in a highly competitive industry.
  • We revised certain previously issued interim financial statement amounts, which could adversely affect investor confidence.
  • RISKS RELATED TO OUR SECURITIES
  • Our share price could be volatile and our trading volume may fluctuate substantially.
  • A decline in the price of our shares of Common Stock could affect our ability to raise further working capital and adversely impact our ability to continue operations.
  • Financial Industry Regulatory Authority (“FINRA”) sales practice requirements may also limit a stockholder’s ability to buy and sell our Common Stock.
  • Our Common Stock has in the past been subject to the “Penny Stock” rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.
  • We currently do not intend to pay dividends on our Common Stock. As result, your only opportunity to achieve a return on your investment is if the price of our Common Stock appreciates.
  • We could issue additional Common Stock, which might dilute the book value of our Common Stock.
  • Future Issuance of Our Common Stock, Preferred Stock, Options and Warrants Could Dilute the Interests of Existing Stockholders.
  • Substantial future sales of shares of our Common Stock in the public market could cause our stock price to fall.
  • We face risks related to Novel Coronavirus (“COVID-19”) which could significantly disrupt our research and development, operations, sales, and financial results.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40